Resilience and Precision in Pharma Development

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Each new chapter in pharmaceutical innovation underscores a simple truth: the path from molecule to medicine is never linear. Scientific discovery, technological evolution, and market demands constantly reshape the landscape, requiring both agility and vision from every stakeholder. This issue of Pharmaceutical Technology® Europe captures the state of that journey, one that is as much about mastering fundamentals as it is about embracing new tools and approaches. Our cover story, “The Evolving Science Behind Formulation Development,” explores strategies across the drug product lifecycle. Vaibhav Sihorkar, PhD, of Aragen Life Sciences, offers insights into problem solving, the role of digital tools, and how geopolitical change is influencing formulation decisions from a CRDMO’s perspective. The complex area of drug formulation is further explored in “Personalized and Patient-Centric Administration of Oral Medicines,” which highlights how individualized therapies are moving forward despite the challenges of scalability and regulation.

On the business front, Ana Ali of RCK Partners provides a perspective on R&D tax relief in the United Kingdom, and Cheryl Barton, PharmaVision, hightlights the companies entering the metabolic dysfunction-associated steatohepatitis arena.

Ensuring product quality remains at the forefront. This issue’s European Regulatory Watch details Europe’s strategy to become an attractive location for life sciences innovation, and the Ask the Expert feature outlines best practices for implementing contamination control strategies.

On the manufacturing front, “Keys to Navigating the Complex Drug Supply Chain” shows how digital tools help manufacturers adapt to ongoing global volatility.

As a whole, this issue reveals an industry strengthening its foundation while embracing innovation. Success now demands not just advanced tools and processes, but collaboration, resilience, and a focus on improving outcomes for patients worldwide.

About the author

Mike Hennessy Jr is Chairman and CEO of MJH Life Sciences®.